和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表

智通财经01-14

智通财经APP讯，和黄医药(00013)发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 (The Lancet)》发表。SACHI是一项赛沃替尼(savolitinib ，沃瑞沙®/ORPATHYS®)和奥希替尼(osimertinib ，泰瑞沙®/TAGRISSO®)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603666888?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 12:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603666888","market":"sh","top_or_hot":-1,"title":"和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 (The Lancet)》发表。SACHI是一项赛沃替尼(savolitinib ，沃瑞沙®/ORPATHYS®)和奥希替尼(osimertinib ，泰瑞沙®/TAGRISSO®)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392627.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 12:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1392627.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 (The Lancet)》发表。SACHI是一项赛沃替尼(savolitinib ，沃瑞沙®/ORPATHYS®)和奥希替尼(osimertinib ，泰瑞沙®/TAGRISSO®)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392627.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1392627.html","article_id":"2603666888","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603666888","pubTimestamp":1768363890,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，和黄医药 发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。中国医学科学院肿瘤医院的王洁教授亦为SACHI 研究的联合主要研究者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK4134":"信息科技咨询与其它服务","BK4531":"中概回港概念","00013":"和黄医药","BK1588":"回港中概股","BK4588":"碎股","BK1191":"制药","BK1587":"次新股","BK4585":"ETF&股票定投概念","III":"信息服务","HCM":"和黄医药"},"translate_title":"Chi-Med (00013) announces the results of SACHI Phase III study published in The Lancet","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1.5,"III":1.5,"00013":1.5},"content_text":"智通财经APP讯，和黄医药(00013)发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 (The Lancet)》发表。SACHI是一项赛沃替尼(savolitinib ，沃瑞沙®/ORPATHYS®)和奥希替尼(osimertinib ，泰瑞沙®/TAGRISSO®)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。赛沃替尼是一种强效、高选择性的口服MET TKI，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。奥希替尼是一种不可逆的第三代EGFR TKI 。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。SACHI研究的联合主要研究者 、上海交通大学医学院附属胸科医院上海肺癌中心主任陆舜教授表示：“已于 《柳叶刀》发表的SACHI研究数据提供了强有力的证据，证实赛沃替尼和奥希替尼的联合疗法可显着改善伴MET扩增的EGFR突变非小细胞肺癌患者的治疗结果。这些结果突显了该联合疗法在应对MET扩增这一关键的耐药机制方面的能力，为这些充满挑战性的患者群体带来具有临床意义的改善。让我们尤其感到鼓舞的是，在既往接受过第三代EGFR TKI治疗的患者中亦观察到了一致疗效。赛沃替尼和奥希替尼的联合疗法提供了一种持续的全口服方案，为亟待新疗法的患者带来了方便且耐受性良好的治疗选择。”中国医学科学院肿瘤医院的王洁教授亦为SACHI 研究的联合主要研究者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603666888","isCrawlerRequest":true}